Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q4 EPS of ($0.75), $0.07 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $13.28 million versus the consensus estimate of $14.91 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.